st us toco fecg iup

ST Case 7

Good signal quality

Summary

33 year old G2 P1. Gest.week 39+5. Admitted to the hospital in spontaneous labor. SROM at 10:00 reported, clear fluid noted. Patient has been contracting since SROM.

11:12 SVE: Cx 4 cm dilated, 100%, vx -1. FSE applied. Epidural given. ST Analysis initiated.
11:22 Poor signal quality noted, the FSE fell off.
11:32 External FHR monitoring started.
11:50 New FSE applied.
13:48 Maternal temperature 38.1 C. IV abx and Tylenol given.
14:41 SVE: Cx 8 cm dilated, 100% effaced, vx 0 station.
16:10 Because of the tachycardia, recurrent late decelerations and elevated maternal temperature the obstetrician decided to perform a caesarean section.
16:58 Cesarean Section. Baby girl born. Apgar Score 10/10/10.

Cord gases

	pH	pCO₂	BE
Artery	7.32	3.3	-1.8
Vein	7.37	27	-1.4

Comment

The FHR pattern was classified as a Yellow Zone tracing. There was optimal signal quality and no ST Event was displayed. According to the STAN guidelines the recommendation for a Yellow Zone trading and no ST Event is “expectant management, closer observation.” If the Yellow Zone tracing is present for greater than 60 minutes (or earlier if FHR shows rapid deterioration of fetal condition), then direct physician assessment of fetal state” is indicated. This physician decided to deliver the fetus by a cesarean section because of tachycardia and the maternal fever.

uploaded 2013-10-03 by Neoventa Medical

© 2018 Neoventa Medical AB | Neoventa Medical Inc. | All rights reserved | These cases are being presented to provide additional learning opportunities and demonstrate the use of STAN and ST Analysis. They are not intended to be a substitute for the product manuals or instructions for use, nor should they be taken to provide specific instructions on how to care for any patient given that the entire clinical picture must be taken into account when administering care. Patient selection and management should always be according to approved indications for use, as well as contraindications, as defined in the clinical guidelines for your point of use.